Aptahem (APTA) Status Update summary

Strategic direction and U.S. listing preparations

• Focused on advancing a lead RNA aptamer candidate targeting sepsis, with strong preclinical and phase 1 results showing efficacy and safety.

• Preparing for a U.S. stock market listing to access better valuation, vibrant investment climate, and regulatory incentives such as FDA pre-check and CNPV programs.

• Transitioning to IFRS accounting standards and engaging U.S. auditors to meet compliance requirements for U.S. investors.

• Hosting an English-language investor webinar to outline strategic direction, U.S. listing plans, and expected benefits of entering the U.S. market.

• Expanding intellectual property with a U.S. provisional patent to cover broader indications, including neurodegenerative diseases and viral infections.

Clinical and market progress

• Lead candidate demonstrated improved survival, reduced inflammation, and no bleeding side effects in preclinical and phase 1 studies.

• Advancing toward a planned Phase 2 clinical program for Apta-1, with protocols targeting both orphan and regular sepsis indications.

• Benchmarking against established drugs showed superior efficacy and safety profile.

• The aptamer market is rapidly growing, with significant commercial potential identified.

Partnership and long-term vision

• Seeking strong partnerships, ideally with big pharma or large biotech, to advance clinical development and commercialization.

• Engaging with academic institutions for further research and development.

• Long-term vision includes advancing the lead candidate through late-stage clinical trials, expanding the pipeline, and establishing multiple collaborations or licensing agreements.